Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30587548.
- Also identified by DOI 10.1158/1078-0432.CCR-18-3858 and PMC identifier 6397678.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune checkpoint inhibitors induce durable responses in some patients with advanced cancer but may simultaneously trigger autoinflammatory immune-related adverse events (irAE). The pathogenesis of irAEs may relate to genetic predisposition, environmental insults, or tumor-host interactions. Elevated expression of certain cytokines may signal subclinical inflammation that evolves into severe irAEs with treatment.<i>See related article by Lim et al., p. 1557</i>.
Medical subject headings
- Cytokines
- Melanoma